17 studies found for:    Transverse Myelitis
Show Display Options
RSS Create an RSS feed from your search for:
Transverse Myelitis
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis
Condition: Transverse Myelitis
Interventions: Drug: Dalfampridine;   Drug: Placebo controlled
2 Recruiting A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder;   Transverse Myelitis;   Optic Neuritis
Intervention:
3 Enrolling by invitation Biobank For MS And Other Demyelinating Diseases
Conditions: Multiple Sclerosis;   Transverse Myelitis;   Neuromyelitis Optica;   Acute Disseminated Encephalomyelitis;   Optic Neuritis
Intervention:
4 Active, not recruiting Serum Auto-Antibodies
Conditions: Multiple Sclerosis;   Myasthenia Gravis;   Transverse Myelitis
Intervention: Other: Blood Draw
5 Completed Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Conditions: Multiple Sclerosis;   Optic Neuritis;   Transverse Myelitis;   Acute Brainstem/Cerebellar Syndrome
Intervention: Drug: interferon beta 1a 30 ug IM once weekly
6 Unknown  Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
Conditions: Acute Disseminated Encephalomyelitis;   Devic's Syndrome;   Marburg's Variant of Multiple Sclerosis;   Balo's Concentric Sclerosis;   Acute Transverse Myelitis
Intervention: Procedure: Plasma exchange
7 Completed Safety and Tolerability of Rituximab in Neuromyelitis Optica
Condition: Neuromyelitis Optica
Intervention: Drug: Rituximab
8 Not yet recruiting Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Bevacizumab
9 Recruiting Maintenance Plasma Exchange for Neuromyelitis Optica
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder;   Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
Intervention: Procedure: Plasma exchange (PLEX)
10 Unknown  Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
Conditions: Multiple Sclerosis;   Neuromyelitis Optica
Intervention:
11 Recruiting Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica
Conditions: Progressive Multiple Sclerosis;   Neuromyelitis Optica.
Intervention: Biological: human umbilical cord mesenchymal stem cells
12 Recruiting C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
Condition: Neuromyelitis Optica
Intervention: Drug: C1-esterase inhibitor (Cinryze)
13 Completed A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)
Conditions: Neuromyelitis Optica;   Myelitis, Transverse;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System
Intervention: Drug: Mitoxantrone
14 Recruiting Hematopoietic Stem Cell Transplant in Devic's Disease
Condition: Devic's Disease
Intervention: Procedure: Hematopoietic stem cell transplantation
15 Completed An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Conditions: Neuromyelitis Optica;   Devic's Disease
Intervention: Drug: Eculizumab
16 Recruiting Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
Condition: Neuromyelitis Optica (NMO)
Intervention: Procedure: AHSCT
17 Not yet recruiting Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Condition: Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: NPB-01

Indicates status has not been verified in more than two years